The low frequency of OS tumors truly deficient in BRCA1/2, in contrast to breast and ovarian cancers, implies that the increased presence of BRCAness in OS arises from alterations in other genes of the HR pathway, each of which contributes to HRD [4]. This evidence concerns the gene BRCA1 and ovarian cancer.